El interés en corto de Polestar Automotive da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Polestar Automotive. Los datos de interés en corto se actualizan cada dos semanas.

Polestar Automotive (NASDAQ:PSNY) Bolsa, Informe de interés en corto

Polestar Automotive

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.

Equities

News

Markets

General

ARKX

PSNY

Polestar registra un aumento del 5,3% en las ventas al por menor en el 4T de 2024, pero reporta una caída del 15% en el total anual.

Ventas de Polestar aumentan 5,3% en el 4T, pero caen un 15% en 2024

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive Holding UK PLC

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

QBTS

D-Wave Announces Fiscal Year 2024 Bookings Will Exceed $23M, Up Approximately 120% YoY

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $25 price target.

Price Target

Reiteration

Analyst Ratings

MDWD

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $25 Price Target

RPRX

Royalty Pharma Says It Has Agreed To Acquire Its External Manager, Rp Management, Which Will Generate Cash Savings Of Greater Than $100M In 2026 And Greater Than $175M In 2030; Company Has Approved A New $3B Share Repurchase Program

<ul>
<li>Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione</li>
<li>Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health</li>
<li>Safety and Efficacy Data Support Initiation of Phase 3 Clinical Trial</li>
</ul>

Biotech

Health Care

CRNX

Crinetics Pharmaceuticals Announced Topline Results From Phase 2 Study Of Atumelnant For Classic Congenital Adrenal Hyperplasia And Adrenocorticotropic Hormone-dependent Cushing's Syndrome

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is recalling 239,382 vehicles in the U.S. over concerns of loss of rearview camera image, the National Highway Traffic Safety Administration (NHTSA)&nbsp;said on Friday.
What Happened:&nbsp;The computer circuit board may short, resulting in loss of rearview camera image, the U.S. auto safety regulator said.
Tesla has released over-the-air software aimed at resolving the issue. The company will also identify vehicles that experienced a circuit board failure or are under stress that may lead to a circuit board failure and replace the affected computers at no cost to the customer, NHTSA said. The recall population includes &nbsp;2024-25 Model 3 and Model S vehicles and 2023-25 Model X and Model Y. 
The company told NHTSA that it is not aware of any collisions, injuries, or fatalities owing to the issue. 
Why It Matters: Earlier this week, NHTSA opened a <a href="https://www.benzinga.com/25/01/42840097/nhtsa-opens-probe-into-26-million-tesla-vehicles-after-complaint-of-crash-involving-actually-smart-summon-feature">probe into 2.6 million Tesla vehicles</a> equipped with the company's full self-driving driver assistance technology following a complaint alleging that the use of its "Actually Smart Summon" feature led to a crash.
Actually, Smart Summon refers to a feature that allows a user to remotely move the vehicle towards themselves or to another nearby location such as a parking lot through the company's phone app.
In 2024, Tesla issued <a href="https://www.benzinga.com/tech/25/01/42755074/tesla-recalls-in-2024-crossed-5-million-but-most-were-fixed-via-software-updates-majority-of-physical-recall">15 recalls, impacting over 5.13 million vehicles</a>. However, a whopping majority of the recalls were fixed with over-the-air (OTA) software updates, and only a select few required vehicle owners to visit a service center to resolve an issue.
Price Action: Tesla shares closed up 0.15% on Thursday at $394.94. The stock is up 1.27% year-to-date, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Tesla has a consensus &#8220;neutral&#8221; rating and a price target of $293.23 based on the ratings of 34 analysts tracked by Benzinga. The highest price target of $515 was issued by Mizuho on Dec. 17, 2024, and the lowest of $24.86 by GLJ Research on Jan. 3.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img loading="lazy" decoding="async" width="435" height="324" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10071336/image-55.png" alt="" class="wp-image-727848" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10071336/image-55.png 435w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10071336/image-55-300x223.png 300w" sizes="(max-width: 435px) 100vw, 435px" /></a></figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42906684/blue-origin-pushes-new-glenn-launch-to-no-earlier-than-sunday" target="_blank" rel="noreferrer noopener">Jeff Bezos' Blue Origin Pushes New Glenn Launch To No Earlier Than Sunday Due To Adverse Weather Conditions</a></li>
</ul>
Image via Shutterstock

Tech

TSLA

Tesla Recalls 239,382 Vehicles In US Over Rearview Camera Image Display Issues

XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) reportedly previewed its new G7 SUV, set to <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">compete in the RMB250,000 ($34,100) segment.</a>
The G7, revealed by XPeng&#8217;s vice president Yu Tao on Weibo, is positioned as a highly competitive model for family users, offering ample space and advanced AI features, <a target="_blank" href="https://cnevpost.com/2025/01/09/xpeng-teases-new-suv-g7/" rel="noreferrer noopener">reports</a> CnEV Post.
Yu also noted that the vehicle will continue the company&#8217;s reputation for &#8220;space monster&#8221; design, similar to its P7+ sedan. Although details remain limited, the initial images of the G7 suggest a sleek and tech-driven design.
XPeng launched the G6 in China in June 2023, with deliveries starting shortly after. The current price of the G6 in China is RMB199,900, the report adds. The updated G6 was recently included in a catalog by China&#8217;s Ministry of Industry and Information Technology, suggesting a facelift may be coming soon.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/42906229/dow-surges-over-100-points-following-fed-minutes-investor-sentiment-declines-greed-index-remains-in-fear-zone" rel="noreferrer noopener">Dow Surges Over 100 Points Following Fed Minutes: Investor Sentiment Declines, Greed Index Remains In &#8216;Fear&#8217; Zone</a>
Earlier this week, the company selected RTI Connext Drive as the core communication technology for its <a target="_blank" href="https://www.benzinga.com//node/42811619" rel="noreferrer noopener">upcoming next-generation vehicle architecture.</a>
Starting with 2026 models, this technology will manage the complex data flow in XPeng cars, enhancing smarter, more efficient designs.
Connext Drive, based on the DDS standard, will ensure seamless communication between vehicle systems, regardless of supplier.
This integration is key to advancing XPeng&#8217;s autonomous driving capabilities and supporting future models&#8217; complex systems without requiring extensive code changes.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, XPEV stock has lost over 2% in the past year. Investors can gain exposure to the stock via&nbsp;VanEck Low Carbon Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMOG#NYSE">SMOG</a>).
Price Action: XPEV shares are trading lower by 1.15% to $12.00 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42907180/rocket-lab-expands-nasa-partnership-with-neutron-under-vadr-contract" target="_blank" rel="noreferrer noopener">Rocket Lab Expands NASA Partnership With Neutron Under VADR Contract</a></li>
</ul>
Photo by Koshiro K on Shutterstock.

Movers

Media

SMOG

XPEV

What's Going On With XPeng Stock On Friday?

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and maintains $2 price target.

APTO

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target

Other Fourth Quarter 2024 Updates
<ul>
<li>Recorlev achieved record number of new starts and referrals.</li>
<li>Gvoke ended the year with approximately 35% market share.</li>
<li>Keveyis maintained a similar number of patients on therapy as Q3 2024.</li>
<li>Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.</li>
<li>Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.</li>
</ul>

Earnings

Guidance

XERS

Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter

GLUE

Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025

Piper Sandler analyst Christopher Raymond initiates coverage on Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) with a Overweight rating and announces Price Target of $72.

Initiation

MNPR

Piper Sandler Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $72

Anticipated 2025 Milestones
<ul>
<li>Part A data from GD2-SADA Phase 1 trial (Trial 1001) expected to be presented in the second quarter of 2025</li>
<li>GD2-SADA optimization data expected to be presented in the second quarter of 2025</li>
<li>Expect to present updates with respect to reprioritized SADA PRIT pipeline, including new high-value target indications and timelines, in the second quarter of 2025</li>
<li>Expect to dose first patient in CD38-SADA Phase 1 trial (Trial 1201) in the first quarter of 2025</li>
<li>Potential for marketing approval of DANYELZA in new ex-U.S. market in 2025</li>
<li>Plan to provide full year 2025 guidance in conjunction with full year 2024 earnings report in the first quarter of 2025</li>
</ul>

YMAB

Y-mAbs Reports Preliminary Estimated 2024 Total Net Revenue Of $88M, Within $87M - $91M Prior Guidance Range; Est $88.221M

These leadership changes were implemented as part of the Company's response to a "Wells Notice" from the Securities and Exchange Commission (the "SEC"), related to certain public disclosures by the Company from March 31, 2022 leading up to May 3, 2022. The Board's independent directors took these actions as a matter of corporate governance best practices and to enable the Company to maintain focus on pursuing its business objectives. The Board believes that the Company, Dr. Mahadevia and Mr. Shukla acted in good faith and consistent with their duties and obligations.

Management

SPRO

Spero Therapeutics Has Appointed Esther Rajavelu As Interim President And CEO, Stepping In For Sath Shukla, Who Has Agreed To A Voluntary Paid Administrative Leave For An Interim Period, The Board Has Also Appointed Director Frank Thomas As Chairman Of The Board, Stepping In For Dr. Ankit Mahadevia

UBS analyst Jay Sole upgrades Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) from Neutral to Buy and raises the price target from $173 to $220.

Upgrades

UBS Upgrades Abercrombie & Fitch to Buy, Raises Price Target to $220

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) from Buy to Buy.

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeuticsto Buy

Piper Sandler analyst Adam Maeder initiates coverage on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Neutral rating and announces Price Target of $252.

Piper Sandler Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $252

TECH

Bio-techne Expands R&D Systems AI-engineered Designer Protein Portfolio To Advance Cell Therapy And Regenerative Medicine

IVVD

Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC, Says Data Submitted To FDA, With Timely Update To PEMGARDA Fact Sheet For Healthcare Providers Anticipated

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from Buy to Buy.

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokineticsto Buy

Y-mAbs Internally Realigns Operations With Establishment Of Two Business Units: Radiopharmaceuticals And DANYELZA; Plans Reduction In Its Current Workforce Of Up To 13%

Piper Sandler analyst Anna Andreeva upgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Neutral to Overweight and raises the price target from $72 to $90.

Piper Sandler Upgrades Nike to Overweight, Raises Price Target to $90

Electric vehicle stocks rip big gains after Beijing developments

Polestar (PSNY) has appointed Jonas Engstrom to the role of COO. As COO, Engstrom's main focus will be the delivery of Polestar's growing car progr...

Polestar appoints Jonas Engstrom COO

Polestar names Jonas Engström as COO

Catalyst Watch: Eyes on electric vehicle deliveries, retail data and housing reads

Tesla: Major Q4 Delivery Disappointment

In a report released today, Daniel Roeska from Bernstein maintained a Sell rating on Polestar Automotive Holding UK (PSNY – Research Report), with ...

Polestar Automotive Holding UK (PSNY) Receives a Sell from Bernstein

2025 Analyst Outlook: Chris Lau On Tariffs, Global Worries, EVs, And An AI Bubble

EV Company News For The Month Of December 2024

Polestar (PSNY) announced retail sales totaled 12,256 cars in Q4 2024, up 5.3% versus Q4 2023, taking total retail sales for the full year to 44,85...

Polestar reports Q4 retail sales up 5.3% to 12,256 cars

Polestar Automotive reports a Q4 increase in retail sales and order intake

ABAT

ASML

ATRA

AVGO

AYRO

BABA

BATT

BCCMY

BLBD

BLNK

BMCLF

BYDDF

BYDDY

BYND

CHPT

CRVO

DNFGF

DNFGY

DRIV

EVTV

FUJHF

FUJHY

FYBR

GELYF

GELYY

GOEV

GOEVW

GWLLF

GWLLY

HNDAF

HOUR

HYLN

HYMTF

IDRV

IIPR

INTC

KARS

KNDI

KULR

KWEB

LAAOF

LAZR

LCID

LPTH

LPTX

MAHMF

MBGAF

MBGYY

MBLY

MESO

MMTOF

MZDAF

MZDAY

NIOIF

NSANF

NSANY

NVDA

POAHF

POAHY

PSNYW

QUBT

RACE

RGTI

RIVN

RNLSY

RNSDF

SGOV

STLA

SWTX

SZKMF

SZKMY

TECK

TOYOF

VALE

VFSWW

VLKAF

VLKPF

VWAGY

VWAPY

WKHS

XIACF

XIACY

XPNGF

Press Releases

Polestar Publishes Q2 2024 Results: 82% Growth in Global Deliveries

Polestar appoints Jean-Francois Mady as CFO

Polestar Announces Date of AGM and Board Changes

Polestar Fully Compliant With Nasdaq Listing Rules

Infosys and Polestar Enter Strategic Collaboration by opening Technology Hub in Bengaluru, India

Polestar Announces Global Volumes for the Third Quarter; to Provide Business and Strategy Update on 16 January 2025

Polestar Now Offers Its Customers Access to One of the World's Largest Charging Networks

Polestar Delivers First Polestar 3 Manufactured in U.S. to North American Customers

Polestar Appoints Jonas Engström Chief Operating Officer

Polestar Announces Global Volumes for the Fourth Quarter

INFY

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Phoenix Motor

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

Comments

Polestar Automotive

Interés en corto

Polestar Automotive (NASDAQ:PSNY) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL